Clinical Trials of Mitotic Kinesin Inhibitors

  • Steven S. RosenfeldEmail author


Abnormal mitotic activity underlies the pathology of a number of human diseases, most notably cancer, and has motivated the search for more specific and less toxic inhibitors of the mitotic process. In this chapter, I review the clinical experience with one group of inhibitors that target mitotic kinesins. I will discuss the results of phase I and II trials with these drugs and place the results of these trials in a context to explain how they can be utilized in future human studies.


Multiple Myeloma Small Molecule Inhibitor Vinca Alkaloid Synthetic Lethality High Mitotic Index 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Rath O, Kozielski F (2012) Kinesins and cancer. Nat Rev Cancer 12:527–539CrossRefPubMedGoogle Scholar
  2. 2.
    Exertier P et al (2013) Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5. Oncotarget 4(12):1–15Google Scholar
  3. 3.
    Carol H et al (2009) Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program. Pediatr Blood Cancer 53:1255–1263CrossRefPubMedCentralPubMedGoogle Scholar
  4. 4.
    El-Nassan HB (2014) Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents. Eur J Med Chem 62:614–631CrossRefGoogle Scholar
  5. 5.
    Koller E et al (2006) Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 as a target for antineoplastic drug development. Cancer Res 66:2059–2066CrossRefPubMedGoogle Scholar
  6. 6.
    Muller C et al (2007) Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells. Cancer Chemother Pharmacol 59:157–164CrossRefPubMedGoogle Scholar
  7. 7.
    Purcell JW et al (2010) Activity of the kinesin spindle protein inhibitor ispinesib (SB- 715992) in models of breast cancer. Clin Cancer Res 16:566–576CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Sakowicz R et al (2004) Antitumor activity of a kinesin inhibitor. Cancer Res 64:3276–3280CrossRefPubMedGoogle Scholar
  9. 9.
    Valensin S et al (2009) KIF11 inhibition for glioblastoma treatment: reason to hope or a struggle with the brain? BMC Cancer 9:196CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Wood KW et al (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proc Natl Acad Sci U S A 107:5839–5844CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Jackson JR et al (2007) Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 7:107–117CrossRefPubMedGoogle Scholar
  12. 12.
    Canta A et al (2009) Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem 16:1315–1324CrossRefPubMedGoogle Scholar
  13. 13.
    Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12:565–571CrossRefPubMedGoogle Scholar
  14. 14.
    Tuxen MK, Hansen SW (1994) Neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 20:191–214CrossRefPubMedGoogle Scholar
  15. 15.
    Morris PG, Fornier MN (2008) Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 14:7167–7172CrossRefPubMedGoogle Scholar
  16. 16.
    Mayer TU et al (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971–974CrossRefPubMedGoogle Scholar
  17. 17.
    Liu X et al (2013) Oncogenic role of kinesin proteins and targeting kinesin therapy. Cancer Sci 104(6):651–656. doi: 10.1111/cas.12138
  18. 18.
    Arnedos M et al (2014) The genetic complexity of common cancers and the promise of personalized medicine: is there any hope? J Pathol 232:274–282CrossRefPubMedGoogle Scholar
  19. 19.
    Blair BG et al (2014) Somatic alterations as the basis for resistance to targeted therapies. J Pathol 232:244–254CrossRefPubMedGoogle Scholar
  20. 20.
    Zheng J (2013) Oncogenic chromosomal translocations and human cancer. Oncol Rep 30:2011–2019PubMedGoogle Scholar
  21. 21.
    Bunting SF, Nussenzweig A (2013) End-joining, translocations and cancer. Nat Rev Cancer 13:443–454CrossRefPubMedGoogle Scholar
  22. 22.
    Weinstein IB et al (1997) Disorders in cell circuitry associated with multistage carcinogenesis: exploitable targets for cancer prevention and therapy. Clin Cancer Res 3:2696–2702PubMedGoogle Scholar
  23. 23.
    Greenman C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158CrossRefPubMedCentralPubMedGoogle Scholar
  24. 24.
    Gorre ME et al (2001) Clinical resistance to STI-571 cancer therapy caused by BCRABL gene mutation or amplification. Science 293:876–880CrossRefPubMedGoogle Scholar
  25. 25.
    Kobayashi S et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. New Engl J Med 352:786–792CrossRefPubMedGoogle Scholar
  26. 26.
    Pao W et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:225–235CrossRefGoogle Scholar
  27. 27.
    Weinstein IB (2002) Addiction to oncogenes—the Achilles heal of cancer. Science 297:63–64CrossRefPubMedGoogle Scholar
  28. 28.
    Weinstein IB, Joe AK (2006) Mechanisms of disease: oncogene addiction—a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448–457CrossRefPubMedGoogle Scholar
  29. 29.
    Weinstein IB, Joe AK (2008) Oncogene addiction—a rationale for molecular targeting in cancer therapy. Cancer Res 68:3077–3080CrossRefPubMedGoogle Scholar
  30. 30.
    Hartwell LH et al (1997) Integrating genetic approaches into the discovery of anti-cancer drugs. Science 278:1064–1068CrossRefPubMedGoogle Scholar
  31. 31.
    Kaelin WG (2005) The concept of synthetic lethality in the context of anti-cancer therapy. Nat Rev Cancer 5:689–698CrossRefPubMedGoogle Scholar
  32. 32.
    Morgan S et al (2011) The cost of drug development: a systematic review. Health Policy 100:4–17CrossRefPubMedGoogle Scholar
  33. 33.
    Liu M, Wang X, Yang Y, Li D, Ren H, Zhu Q, Chen Q, Han S, Hao J, Zhou J (2010) Ectopic expression of the microtubule-dependent motor protein Eg5 promotes pancreatic tumourigenesis. J Pathol 221(2):221–228CrossRefPubMedGoogle Scholar
  34. 34.
    Ding S, Xing N, Lu J, Zhang H, Nishizawa K, Liu S, Yuan X, Qin Y, Liu Y, Ogawa O, Nishiyama H (2011) Overexpression of Eg5 predicts unfavorable prognosis in non- muscle invasive bladder urothelial carcinoma. Int J Urol 18(6):432–438CrossRefPubMedGoogle Scholar
  35. 35.
    Sun D, Lu J, Ding K, Bi D, Niu Z, Cao Q, Zhang J, Ding S (2013) The expression of Eg5 predicts a poor outcome for patients with renal cell carcinoma. Med Oncol 30(1):476CrossRefPubMedGoogle Scholar
  36. 36.
    Gomeza HL et al (2012) Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28- day schedule in patients with no prior treatment for advanced breast cancer. Anti Cancer Drugs 23:335–341CrossRefGoogle Scholar
  37. 37.
    Blagden SP et al (2008) A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours. Brit J Cancer 98:894–899CrossRefPubMedCentralPubMedGoogle Scholar
  38. 38.
    Burris HA III et al (2011) A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Invest New Drugs 29:467–472CrossRefPubMedGoogle Scholar
  39. 39.
    Souid A-K et al (2010) A pediatric phase I trial and pharmacokinetic study of ispinesib: a children’s oncology group phase I consortium study. Pediatr Blood Cancer 55:1323–1328CrossRefPubMedCentralPubMedGoogle Scholar
  40. 40.
    Escudier B et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. New Engl J Med 356:125–134CrossRefPubMedGoogle Scholar
  41. 41.
    Holen KD et al (2011) A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol 67:447–454CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Gerecitano JF et al (2013) A phase I trial of the kinesin spindle protein (Eg5) inhibitor AZD4877 in patients with solid and lymphoid malignancies. Invest New Drugs 31:355–362CrossRefPubMedGoogle Scholar
  43. 43.
    Infante JR et al (2012) A phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol 69:165–172CrossRefPubMedGoogle Scholar
  44. 44.
    Holen K et al (2012) A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumors. Invest New Drugs 30:1088–1095CrossRefPubMedCentralPubMedGoogle Scholar
  45. 45.
    Khoury HJ et al (2012) A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Cancer 118:3556–3564CrossRefPubMedGoogle Scholar
  46. 46.
    Lonial S et al (2013) Prolonged survival and improved response rates with ARRY-520 in relapsed/refractory multiple myeloma (RRMM) patients with low α-1 acid glycoprotein (AAG) levels: results from a phase 2 study. Abstract #285, American Society of Hematology annual meeting, 2013Google Scholar
  47. 47.
    Chari A et al (2013) A phase 1 study of ARRY-520 with bortezomib (BTZ) and dexamethasone (dex) in relapsed or refractory multiple myeloma (RRMM). Abstract #1938, American Society of Hematology annual meeting, 2013Google Scholar
  48. 48.
    Shah J et al (2013) Phase 1 study of the novel kinesin spindle protein inhibitor ARRY- 520 + carfilzomib (Car) in patients with relapsed and/or refractory multiple myeloma (RRMM) phase 1 study of the novel kinesin spindle protein inhibitor ARRY-520 + carfilzomib (Car) in patients with relapsed and/or refractory multiple myeloma (RRMM). Abstract #1982, American Society of Hematology annual meeting, 2013Google Scholar
  49. 49.
    Komlodi-Pasztor E et al (2011) Mitosis is not a key target of microtubule agents in patient tumors. Nat Rev Clin Oncol 8:244–250CrossRefPubMedGoogle Scholar
  50. 50.
    Lee CW et al (2008) A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 26:249–255CrossRefPubMedGoogle Scholar
  51. 51.
    Tang PA et al (2008) Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Invest New Drugs 26:257–264CrossRefPubMedGoogle Scholar
  52. 52.
    Knox JJ et al (2008) A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials. Invest New Drugs 26:265–272CrossRefPubMedGoogle Scholar
  53. 53.
    Beer TM et al (2008) Southwest oncology group phase II study of ispinesib in androgen independent prostate cancer previously treated with taxanes. Clin Genitourin Cancer 6:103–109CrossRefPubMedGoogle Scholar
  54. 54.
    Lee RT et al (2008) A university of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer 6:21–24CrossRefPubMedCentralPubMedGoogle Scholar
  55. 55.
    Kantarjian HM et al (2012) Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 30:1107–1115CrossRefPubMedCentralPubMedGoogle Scholar
  56. 56.
    Owens B (2013) Kinesin inhibitor marches toward first-in-class pivotal trial. Nat Med 19:1550CrossRefPubMedGoogle Scholar
  57. 57.
    Chung V et al (2012) First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemother Pharmacol 69:733–741CrossRefPubMedGoogle Scholar
  58. 58.
    Talapatra SK et al (2013) Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. J Med Chem 56:6317–6329CrossRefPubMedGoogle Scholar
  59. 59.
    Gifford KM et al (2014) SRC phosphorylation regulates the human kinesin-5, Eg5, and disrupts the binding of Eg5 inhibitors. Biophys J 106:780aCrossRefGoogle Scholar
  60. 60.
    Wheeler DL et al (2009) The role of Src in solid tumors. Oncologist 14:667–678CrossRefPubMedCentralPubMedGoogle Scholar
  61. 61.
    Gee CE et al (1986) Differentiation of myeloid cells is accompanied by increased levels of pp6Oc-src protein and kinase activity. Proc Natl Acad Sci U S A 83:5131–5135CrossRefPubMedCentralPubMedGoogle Scholar
  62. 62.
    Komlodi-Pasztor E et al (2012) Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin Cancer Res 18:51–63CrossRefPubMedGoogle Scholar
  63. 63.
    Mitchison TJ (2012) The proliferation rate paradox in antimitotic chemotherapy. Mol Biol Cell 23:1–6CrossRefPubMedCentralPubMedGoogle Scholar
  64. 64.
    Drewinko B (1981) The growth fraction of human myeloma cells. Blood 57:333–338PubMedGoogle Scholar
  65. 65.
    Rosell R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239–246CrossRefPubMedGoogle Scholar
  66. 66.
    Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322CrossRefPubMedGoogle Scholar
  67. 67.
    Andres G, Chiesa-Vottero AG et al (2003) Comparison of proliferation indices in glioblastoma multiforme by whole tissue section vs tissue microarray. Am J Clin Pathol 120:902–908CrossRefGoogle Scholar
  68. 68.
    Yamaguchi R, Dutta A (2000) Proteasome inhibitors alter the orderly progression of DNA synthesis during S-phase in HeLa cells and lead to rereplication of DNA. Exp Cell Res 261:271–283CrossRefPubMedGoogle Scholar
  69. 69.
    Poot M et al (1992) Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia. Mutat Res 270:185–189CrossRefPubMedGoogle Scholar
  70. 70.
    McBride WH et al (2003) The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 22:5755–5773CrossRefPubMedGoogle Scholar
  71. 71.
    Tabernero J et al (2013) First in humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3:406–417CrossRefPubMedGoogle Scholar
  72. 72.
    Lidar Z et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472–479CrossRefPubMedGoogle Scholar
  73. 73.
    Bruce JN et al (2011) Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery 69(6):1272–1279CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2015

Authors and Affiliations

  1. 1.Department of Cancer Biology and Rose Ella Burkhardt Brain Tumor CenterCleveland Clinic FoundationClevelandUSA

Personalised recommendations